title: Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia.
abstract: BACKGROUND
  Cancer patients with fever and neutropenia currently are assessed on clinical grounds only. The current study prospectively evaluated the efficacy of baseline procalcitonin (PCT) in the detection of bacteremia and in the prediction of outcome in patients with solid tumors and febrile neutropenia.
  
  
  METHODS
  PCT levels were determined at baseline and every 48 hours in 104 patients undergoing chemotherapy who developed fever (axillary temperature > 38 degrees C on 2 occasions or > 38.3 degrees C in a single record) and neutropenia (absolute neutrophil count < 500 cells/microL).
  
  
  RESULTS
  The median baseline PCT values were significantly higher in patients who had microbiologically documented infections (1.24 ng/mL) compared with patients who had clinically documented infections (0.27 ng/mL) or fever of unknown origin (0.21 ng/mL; P < 0.01). Accordingly, a PCT cut-off value of 0.5 ng/mL was reached more frequently in patients who had microbiologically documented infections compared with patients who had clinically documented infections or fever of unknown origin (66.7% vs. 13.4%, respectively; P < 0.001). Furthermore, this threshold also was associated with an increased likelihood of treatment failure (70.0% vs. 14.9%; P < 0.001). All 4 septic patients and all 5 patients who ultimately died presented PCT values 5-fold to 10-fold greater than the median values. Clinical evaluation in combination with baseline PCT assessment appeared to improve clinical risk evaluation alone.
  
  
  CONCLUSIONS
  Baseline PCT levels were higher in patients who had febrile neutropenia with bacteremia compared with patients who had clinical infections or fever of unknown origin. PCT helped to identify patients who had microbiologic infections and patients who were at high risk of treatment failure, and PCT may constitute a complementary tool in the initial assessment of such patients.
authors.affiliation: Division of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Jimeno
authors.forename: Adelaida
authors.initials: A
authors.lastname: García-Velasco
authors.forename: Olga
authors.initials: O
authors.lastname: del Val
authors.forename: Enrique
authors.initials: E
authors.lastname: González-Billalabeitia
authors.forename: Susana
authors.initials: S
authors.lastname: Hernando
authors.forename: Rosario
authors.initials: R
authors.lastname: Hernández
authors.forename: Alfonso
authors.initials: A
authors.lastname: Sánchez-Muñoz
authors.forename: Ana
authors.initials: A
authors.lastname: López-Martín
authors.forename: Ignacio
authors.initials: I
authors.lastname: Durán
authors.forename: Luis
authors.initials: L
authors.lastname: Robles
authors.forename: Hernán
authors.initials: H
authors.lastname: Cortés-Funes
authors.forename: Luis
authors.initials: L
authors.lastname: Paz-Ares
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood*; D002116:Calcitonin / Q000097:blood*; D015740:Calcitonin Gene-Related Peptide; D003937:Diagnosis, Differential; D005260:Female; D005334:Fever / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood*; D009503:Neutropenia / Q000097:blood*; D011379:Prognosis; D011446:Prospective Studies; D011498:Protein Precursors / Q000097:blood*; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; C000606589:CALCA protein, human; D011498:Protein Precursors; D002116:Calcitonin; D015740:Calcitonin Gene-Related Peptide